Immunotherapy combo shows promise against stubborn breast cancer
Disease control
Completed
This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (carboplatin) helps control breast cancer that has returned on the chest wall. 76 women with hormone-resistant or triple-negative breast cancer took part. The goal was to see if the com…
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated May 15, 2026 11:53 UTC